KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Acadia Pharmaceuticals (ACAD) over the last 14 years, with Dec 2024 value amounting to $436.9 million.

  • Acadia Pharmaceuticals' Total Non-Current Liabilities rose 3.97% to $399.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $399.6 million, marking a year-over-year increase of 3.97%. This contributed to the annual value of $436.9 million for FY2024, which is 44.65% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Total Non-Current Liabilities is $436.9 million, which was up 44.65% from $302.1 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $436.9 million in FY2024 and a low of $150.4 million during FY2020.
  • Over the past 3 years, Acadia Pharmaceuticals' median Total Non-Current Liabilities value was $302.1 million (recorded in 2023), while the average stood at $305.8 million.
  • Data for Acadia Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY surged of 85.28% (in 2020) over the last 5 years.
  • Acadia Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $150.4 million in 2020, then climbed by 1.17% to $152.2 million in 2021, then grew by 17.17% to $178.3 million in 2022, then spiked by 69.38% to $302.1 million in 2023, then surged by 44.65% to $436.9 million in 2024.